ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ADC Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11161
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ADC Therapeutics SA (ADCT) is a pharmaceutical company that develops a pipeline of proprietary antibody drug conjugates for the treatment of both solid and hematological cancers. The company offers combining monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine -based warheads to selectively kill cancer cells. It conducts research on next-generation cancer biologic therapies. ADCT targets a wide range of cancers such as breast lung, prostate, renal, blood cancer, and others. The company has exclusive technology license partnership with Spirogen for the development of PBD-based Antibody-Drug-Conjugates. It also has corporate partnerships with MedImmune, Cancer Research Technology, Genmab, and others. ADCT is headquartered in Lausanne, Switzerland.

ADC Therapeutics SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
Private Equity 14
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
Partnerships 15
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
Licensing Agreements 20
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
Equity Offering 29
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA – Key Competitors 32
ADC Therapeutics SA – Key Employees 33
ADC Therapeutics SA – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Product Approvals 35
Jun 09, 2017: ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma 35
Clinical Trials 36
Apr 13, 2018: Promising pre-clinical data supporting BerGenBios pipeline to be published and presented at upcoming leading conferences 36
Apr 11, 2018: ADC Therapeutics to Present New Investigational Antibody-Drug Conjugate ADCT-601 at the American Association for Cancer Research (AACR) Annual Meeting 37
Apr 11, 2018: ADC Therapeutics to Present on its Lymphoid Malignancies Drug Candidate DCT-301 at the American Association for Cancer Research (AACR) Annual Meeting 38
Dec 11, 2017: ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301 39
Dec 11, 2017: ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402 41
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data for ADCT-402 at American Society of Hematology 2017 Annual Meeting 43
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data on ADCT-301 at the American Society of Hematology 2017 Annual Meeting 44
Jun 16, 2017: ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma 45
Jun 16, 2017: ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA, Key Competitors 32
ADC Therapeutics SA, Key Employees 33
ADC Therapeutics SA, Other Locations 34

List of Figures
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Quest Diagnostics Incorporated:企業のM&A・事業提携・投資動向
    Quest Diagnostics Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Quest Diagnostics Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Syndax Pharmaceuticals Inc (SNDX):企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • Dubai Electricity and Water Authority:企業の発電所・SWOT分析2018
    Dubai Electricity and Water Authority - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • BaroFold Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BaroFold Inc (BaroFold) is a biotechnology company that provides protein herapeutics for bio-pharmaceutical companies, research institutions, and government agencies. The company applies its Pressure Enabled Protein Manufacturing (PreEMT) technology that improves the tolerability, efficacy a …
  • Standard Motor Products Inc:企業の戦略・SWOT・財務情報
    Standard Motor Products Inc - Strategy, SWOT and Corporate Finance Report Summary Standard Motor Products Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • New York Power Authority:企業の戦略・SWOT・財務分析
    New York Power Authority - Strategy, SWOT and Corporate Finance Report Summary New York Power Authority - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • BrainStorm Cell Therapeutics Inc (BCLI):企業の財務・戦略的SWOT分析
    Summary BrainStorm Cell Therapeutics Inc (BrainStorm Cell Therapeutics) formerly Golden Hand Resources Inc is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy pl …
  • Sabine Oil & Gas Corporation-石油・ガス分野:企業M&A・提携分析
    Summary Sabine Oil & Gas Corporation (Sabine Oil), formerly known as Forest Oil Corporation is an independent oil and gas company. The company focuses on acquisition, exploitation, development and exploration of oil and natural gas properties onshore in the US. Its core areas of operations include E …
  • CIRCOR Aerospace Products Group:企業の戦略・SWOT・財務情報
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Ahn-Gook Pharmaceutical Co Ltd (001540)-製薬・医療分野:企業M&A・提携分析
    Summary Ahn-Gook Pharmaceutical Co Ltd (Ahn-Gook Pharmaceutical) is a developer and supplier of medicines. The company provides health functional food, medical device, ethical drug, over the counter drugs, and others. Its products include acefenac tab, ahngook carvedilol tab, ahngook cefaclor cap, a …
  • Alnylam Pharmaceuticals Inc (ALNY)-医療機器分野:企業M&A・提携分析
    Summary Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiova …
  • National Research Corp (NRCIB):企業の財務・戦略的SWOT分析
    Summary National Research Corp (NRC) is a healthcare organization that provides market insight solutions. The company’s solutions include experience collection, market insights, transparency of experience data and governance. It offers market insights solutions that allow the tracking of awareness, …
  • GlaxoSmithKline Plc (GSK)-医療機器分野:企業M&A・提携分析
    Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respira …
  • Polimex-Mostostal SA (PXM):企業の財務・戦略的SWOT分析
    Polimex-Mostostal SA (PXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Vivergo Fuels Limited:企業の戦略的SWOT分析
    Vivergo Fuels Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Malayan Flour Mills Berhad:戦略・SWOT・企業財務分析
    Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report Summary Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Barclays Bank Plc:企業のM&A・事業提携・投資動向
    Barclays Bank Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Barclays Bank Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Tecpetrol S.A.:企業の戦略・SWOT・財務分析
    Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report Summary Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Surgical Innovations Group Plc (SUN):医療機器:M&Aディール及び事業提携情報
    Summary Surgical Innovations Group plc (Surgical Innovations) designs, develops, manufactures and markets medical devices for use in minimally invasive surgery (MIS) and industrial markets. The company offers SI branded products and products for selected original equipment manufacturer (OEM) partner …
  • SPX Flow Inc (FLOW):企業の財務・戦略的SWOT分析
    SPX Flow Inc (FLOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆